FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807266921> ?p ?o ?g. }

• W2807266921 abstract "An important component of the RAS signalling pathway, the RAS p21 oncogene, is frequently hyperactivated in breast cancer. Its expression in tumor tissue has been linked to poor clinical outcome. This study was designed to evaluate the clinical relevance of RAS p21 levels in peripheral blood in a large cohort of metastatic breast cancer patients. Two hundred fifty-one patients with metastatic breast cancer were enrolled in this prospective, multicentre, open-label, non-randomized study. Blood samples were collected before start of first-line or later-line treatment. RAS p21 was determined using a sandwich-type ELISA immunoassay. For the determination of the cutoff, blood samples from age-matched healthy controls were analyzed. A value above 452 pg/ml was regarded as elevated (mean + 2 x SD). In the univariate survival analysis, two other cutoffs were considered as well (50th and 75th percentile of patients, i.e. 229 pg/ml and 320 pg/ml). Circulating tumor cells (CTCs) were detected using the CellSearch system. 29 of 251 (12%) patients had RAS p21 levels above the cut-off level of 452 pg/ml. Clinical-pathological parameters, such as hormone receptor and HER2 status, line of therapy and CTC status, did not correlate with RAS p21 levels. Elevated RAS p21 was significantly associated with shorter progression-free and overall survival in the univariate analysis (median PFS: 3.9 months [95%-CI: 1.8–6.0] for patients with elevated RAS p21 levels versus 8.5 months [95%-CI: 7.4–9.5] with non-elevated levels [p = 0.01]; median OS: 7.1 months [95%-CI: 0.3–14.2] versus not reached [p = 0.002], respectively). When RAS p21 cutoffs other than 452 pg/ml were considered, elevated RAS p21 was significantly associated with OS but not with PFS. Classical clinical-pathological factors were included into a multivariate Cox regression analysis. In addition, factors previously shown to influence survival in a univariate analysis, such as serum HER2, CAIX and TIMP1, were included as well. In the multivariate analysis, RAS p21, presence of ≥5 CTCs per 7.5 ml blood, higher grading and higher line of therapy remained independent predictors of shorter OS. Metastatic breast cancer patients with elevated levels of circulating RAS p21 have significantly worse clinical outcome. Hypothetically, these patients might benefit from therapeutic strategies targeting RAS pathway. Current Controlled Trials ISRCTN59722891 (DETECT); trial registration date: April, 17th 2010; the trial was registered retrospectively." @default.
• W2807266921 created "2018-06-13" @default.
• W2807266921 creator A5003887595 @default.
• W2807266921 creator A5008649645 @default.
• W2807266921 creator A5011926030 @default.
• W2807266921 creator A5017728105 @default.
• W2807266921 creator A5021290996 @default.
• W2807266921 creator A5024505267 @default.
• W2807266921 creator A5040331693 @default.
• W2807266921 creator A5045891981 @default.
• W2807266921 creator A5048105827 @default.
• W2807266921 creator A5078288046 @default.
• W2807266921 creator A5085546495 @default.
• W2807266921 creator A5086791040 @default.
• W2807266921 creator A5088637879 @default.
• W2807266921 date "2018-05-08" @default.
• W2807266921 modified "2023-10-18" @default.
• W2807266921 title "Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer" @default.
• W2807266921 cites W131063584 @default.
• W2807266921 cites W1493551679 @default.
• W2807266921 cites W1514144742 @default.
• W2807266921 cites W1955547739 @default.
• W2807266921 cites W1967913221 @default.
• W2807266921 cites W1986567580 @default.
• W2807266921 cites W1990602667 @default.
• W2807266921 cites W1994110056 @default.
• W2807266921 cites W1998203489 @default.
• W2807266921 cites W1999441881 @default.
• W2807266921 cites W2007444312 @default.
• W2807266921 cites W2007916146 @default.
• W2807266921 cites W2017205453 @default.
• W2807266921 cites W2020016182 @default.
• W2807266921 cites W2020283335 @default.
• W2807266921 cites W2040896405 @default.
• W2807266921 cites W2043901294 @default.
• W2807266921 cites W2046691924 @default.
• W2807266921 cites W2052016477 @default.
• W2807266921 cites W2055961110 @default.
• W2807266921 cites W2060605982 @default.
• W2807266921 cites W2080719056 @default.
• W2807266921 cites W2085768679 @default.
• W2807266921 cites W2109031404 @default.
• W2807266921 cites W2112645006 @default.
• W2807266921 cites W2114843025 @default.
• W2807266921 cites W2124054103 @default.
• W2807266921 cites W2130672532 @default.
• W2807266921 cites W2134471382 @default.
• W2807266921 cites W2137297899 @default.
• W2807266921 cites W2138501293 @default.
• W2807266921 cites W2146006182 @default.
• W2807266921 cites W2160984505 @default.
• W2807266921 cites W2161884651 @default.
• W2807266921 cites W2222582708 @default.
• W2807266921 cites W2262414037 @default.
• W2807266921 cites W2284540638 @default.
• W2807266921 cites W2330647747 @default.
• W2807266921 cites W2336083847 @default.
• W2807266921 cites W2409673033 @default.
• W2807266921 cites W2437784975 @default.
• W2807266921 cites W2564847411 @default.
• W2807266921 cites W2626446213 @default.
• W2807266921 cites W2794294747 @default.
• W2807266921 cites W4290348479 @default.
• W2807266921 cites W1972462429 @default.
• W2807266921 cites W2399158193 @default.
• W2807266921 doi "https://doi.org/10.1186/s12885-018-4282-0" @default.
• W2807266921 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5941516" @default.
• W2807266921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29739347" @default.
• W2807266921 hasPublicationYear "2018" @default.
• W2807266921 type Work @default.
• W2807266921 sameAs 2807266921 @default.
• W2807266921 citedByCount "5" @default.
• W2807266921 countsByYear W28072669212018 @default.
• W2807266921 countsByYear W28072669212019 @default.
• W2807266921 countsByYear W28072669212021 @default.
• W2807266921 crossrefType "journal-article" @default.
• W2807266921 hasAuthorship W2807266921A5003887595 @default.
• W2807266921 hasAuthorship W2807266921A5008649645 @default.
• W2807266921 hasAuthorship W2807266921A5011926030 @default.
• W2807266921 hasAuthorship W2807266921A5017728105 @default.
• W2807266921 hasAuthorship W2807266921A5021290996 @default.
• W2807266921 hasAuthorship W2807266921A5024505267 @default.
• W2807266921 hasAuthorship W2807266921A5040331693 @default.
• W2807266921 hasAuthorship W2807266921A5045891981 @default.
• W2807266921 hasAuthorship W2807266921A5048105827 @default.
• W2807266921 hasAuthorship W2807266921A5078288046 @default.
• W2807266921 hasAuthorship W2807266921A5085546495 @default.
• W2807266921 hasAuthorship W2807266921A5086791040 @default.
• W2807266921 hasAuthorship W2807266921A5088637879 @default.
• W2807266921 hasBestOaLocation W28072669211 @default.
• W2807266921 hasConcept C121608353 @default.
• W2807266921 hasConcept C126322002 @default.
• W2807266921 hasConcept C143998085 @default.
• W2807266921 hasConcept C144301174 @default.
• W2807266921 hasConcept C2775930923 @default.
• W2807266921 hasConcept C2779013556 @default.
• W2807266921 hasConcept C2780140570 @default.
• W2807266921 hasConcept C2781018059 @default.
• W2807266921 hasConcept C29537977 @default.
• W2807266921 hasConcept C38180746 @default.

• next